China SXT Pharmaceuticals (NASDAQ:SXTC) Given "Sell (E+)" Rating at Weiss Ratings
Weiss Ratings has reaffirmed a "sell (e+)" rating for China SXT Pharmaceuticals (NASDAQ:SXTC) in a recent report. The stock traded down to $1.56, with an average rating of "sell" from analysts. Despite a recent upgrade from Wall Street Zen to a "hold" rating, the company has a debt-to-equity ratio of 0.01 and a current ratio of 3.54. The stock has fluctuated between a low of $0.95 and a high of $7.84 over the past year.
China SXT Pharmaceuticals (NASDAQ:SXTC - Get Free Report)'s stock had its "sell (e+)" rating reissued by investment analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.
Separately, Wall Street Zen upgraded China SXT Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, August 2nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of "Sell".
Read Our Latest Stock Analysis on China SXT Pharmaceuticals
China SXT Pharmaceuticals Price Performance
Shares of NASDAQ:SXTC traded down $0.08 during trading on Wednesday, reaching $1.56. 32,272 shares of the stock were exchanged, compared to its average volume of 109,840. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.54 and a quick ratio of 3.40. China SXT Pharmaceuticals has a 1-year low of $0.95 and a 1-year high of $7.84. The stock has a fifty day moving average of $1.62 and a two-hundred day moving average of $1.82.
China SXT Pharmaceuticals Company Profile
(Get Free Report)China SXT Pharmaceuticals, Inc, a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.
Featured Stories
- Five stocks we like better than China SXT Pharmaceuticals
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Lowe’s vs. Home Depot: Which Benefits More From Lower Rates?
- Find and Profitably Trade Stocks at 52-Week Lows
- These 5 Beaten-Down Tech Stocks Could Catch Fire Next
- Industrial Products Stocks Investing
- Falcon Flex Drives Growth as CrowdStrike Bets on AI Security
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in China SXT Pharmaceuticals Right Now?
Before you consider China SXT Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and China SXT Pharmaceuticals wasn't on the list.
While China SXT Pharmaceuticals currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
